|Title:||Crystalline pharmaceutical and methods of preparation and use thereof|
|Abstract:||Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##|
|Inventor(s):||Burnier; John (Pacifica, CA)|
|Assignee:||SARcode Bioscience Inc. (Brisbane, CA)|
1. A composition comprising an isolated compound of Formula I: ##STR00020## wherein said compound is synthesized according to a method comprising the steps: performing
hydrolysis of Formula AA with a base: ##STR00021## wherein R is a carbon containing moiety: and isolating the compound of Formula I, wherein said composition is essentially free of a chemical catalyst.
2. The composition of claim 1, wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups.
3. The composition of claim 1, wherein R is benzyl.
4. The composition of claim 1, wherein the base is sodium hydroxide.